 |
1 Disease |  |
1 Trial |
|
1 Trial |  |
42 News |  |
- |||| Maball (rituximab biosimilar) / Hetero, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Heterogeneity: There is also heterogeneity, redundancy and synergy of cytokines in Lupus with a complex interplay between BLys, IL17 & IL21 Hence the failure of single agent Rituximab. Those cytokines can substitute (or synergise) in different contexts. (Twitter) - Jan 10, 2023
- |||||| Maball (rituximab biosimilar) / Hetero, Aliqopa (copanlisib) / Bayer, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Heterogeneity: In a few minutes @DrJulieVose will share #ESMO21 #Lymsm🔑 takeaways: ⭐️ copanlisib plus rituximab resulted in 52% reduction in disease progression ⭐️ high heterogeneity of tumor micoenvironment in Hodgkin before PD1 inhibitor therapy 💻 Join Free: https://t.co/4yhAwVdeDa (Twitter) - Oct 23, 2021
- || Maball (rituximab biosimilar) / Hetero, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Impfversager auch bei jungen Menschen (nach heterologer Impfung). Keinerlei Antikörper nach AZ+BT aufgrund von B-cell-depletion #Rituximab (Twitter) - Aug 10, 2021